ClinicalTrials.gg
CompletedNCT05758948Updated Oct 16, 2026

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

An observational study in Metastatic Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Hellenic Cooperative Oncology Group · Observational

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
101
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.

Planned enrollment
13th of 14
101 · median 423
Started
1998
the only one that year
Observational
14 of 18
3 open now
Registered
11th of 18
by date

Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 1998, is one of 14 observational ones, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, or all of them as a file.
02

Study summary

To determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of DN- MBC aiming in comprehending the biology and highlighting potential novel treatment options for the disease.

Read the detailed description

The value of this study is based on the fact that DN-MBC is rare, seems to be different from early and relapsed breast cancer and has not been studied as distinct disease. To achieve the objective of this study blood and tissue sample from patients diagnosed with DN-MBC will be further analyzed using next generation sequencing (NGS), in order to map the molecular/genetic characteristics of DN-MBC and to detect germline and somatic pathogenic variants. All the results will be associated with the clinicopathological characteristics of the patients.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients will be selected from community or academic or private hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed for the provision of the biological material for research purposes
  2. Diagnosis of de novo MBC ( confirmed)
  3. Age >18 years
  4. Blood samples
  5. Tumor tissue block from at least on disease site, primary (preferably) or

Exclusion criteria

Exclusion Criteria:

Inadequate MBC tissue

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
101 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients diagnosed with de novo metastatic breast cancer

    Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)

    Diagnostic Test: NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue

Interventions

  • Diagnostic testNGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue

    In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants

06

What researchers measure

Primary outcomes

  1. Number of participants with somatic pathogenic variants in denovo metastatic breast cancer

    Time frame: up to 12 months

  2. Number of participants with germline pathogenic variants in denovo metastatic breast cancer

    Time frame: up to 12 months

Secondary outcomes

  1. Definition of the somatic pathogenic variants measured with Next Generation Sequencing

    Time frame: up to 12 months

  2. Collection of clinicopathological characteristics of the included patients from patient's medical file

    Time frame: up to 12 months

  3. Definition of the germline pathogenic variants measured with Next Generation Sequencing

    Time frame: up to 12 months

07

Study locations

1 site
  • Evangelia Moirogiorgou
    Athens, Greece
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 1998 to primary completion in Oct 2025, 327 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 327 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2010 → Oct 2025 and completion Jun 2023 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Mar 8, 2023
StartActual
Jul 5, 1998
Primary completionActual
Oct 7, 2025was Oct 2010
CompletionActual
Apr 15, 2026was Jun 2023
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 16, 2026
Primary completion
Oct 5, 2010→Oct 7, 2025
Oct 16, 2026
Study completion
Jun 2023→Apr 15, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Status unknown→Completed
    Primary completion Oct 5, 2010→Oct 7, 2025
    Study completion Jun 2023→Apr 15, 2026 (now actual)
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05758948
Lead sponsor
Hellenic Cooperative Oncology Group
Collaborators
Hellenic Society of Medical Oncology
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Jul 5, 1998
Primary completion
Oct 7, 2025
Completion
Apr 15, 2026
Last update
Oct 16, 2026

Study contacts

EVANGELIA MOIROGIORGOU
principal investigator · YGEIA Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion